Share Purchase by Chief Financial Officer

RNS Number : 8510R

ReNeuron Group plc

03 March 2023

 

ReNeuron Group plc

("ReNeuron" or "the Group")

Share Purchase by Chief Financial Officer

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies , announces that John Hawkins, CFO of the Company, has today purchased 47,668 of the Company's ordinary shares of 1p each ("Ordinary Shares").

Name	Title	Number of Ordinary Shares purchased	Resulting beneficial interest in the Company's Ordinary Shares	Percentage of Company's Total Voting Rights
John Hawkins	Chief Financial Officer	47,668	147,668	0.258%

  ENDS

Enquiries:

ReNeuron		www.reneuron.com/investors
Iain Ross, Chairman		Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking)		[phone]
Allenby Capital Limited (Joint Broker)		[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)		[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects.  ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit  www.reneuron.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Michael Hawkins
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 10.489p 47,668
d)	Aggregated information	47,668 ordinary shares at an average price of 10.489p at a total value of £4,999.90
e)	Date of the transaction	03 March 2023
f)	Place of the transaction	London Stock Exchange AIM Market

 

END

 

 

DSHJJMLTMTJMMJJ